Patents by Inventor Dean E McNulty

Dean E McNulty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of screening for agonists and agonists of the interaction between the AXOR8 and AXOR52 receptors and ligands thereof
    Publication number: 20030059856
    Abstract: Disclosed are methods for discovering agonists and antagonists of the interaction between monkey AXOR8, human AXOR8, and human AXOR52 receptors with their natural ligands: human BV8-a, mouse BV8-a, frog BV8, human BV8-b, human PRO1186, human PRO1186 variant, and mamba intestinal toxin (herein “MIT”).
    Type: Application
    Filed: April 25, 2002
    Publication date: March 27, 2003
    Inventors: Robert S. Ames, Henry M. Sarau, J. Randall Slemmon, Dean E. McNulty, Lisa Vawter, James J. Foley
  • Antibodies produced against cytokine suppressive anti-inflammatory drug binding proteins
    Patent number: 6361773
    Abstract: This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.
    Type: Grant
    Filed: October 1, 1997
    Date of Patent: March 26, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: John C. Lee, Jerry L. Adams, Timothy F. Gallagher, David W. Green, John Richard Heys, Peter C. McDonnell, Dean E. McNulty, Peter R. Young, James E. Strickler
  • Human urotensin II
    Patent number: 6348585
    Abstract: Human Urotensin II polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human Urotensin II polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Grant
    Filed: January 3, 2000
    Date of Patent: February 19, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Jeffrey Culp, Catherine E Ellis, Dean E McNulty
  • Human urotensin II
    Patent number: 6075137
    Abstract: Human Urotensin II polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human Urotensin II polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Grant
    Filed: February 20, 1998
    Date of Patent: June 13, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: Jeffrey Culp, Catherine E Ellis, Dean E McNulty
  • Polynucleotides encoding cytokine suppressive anti-inflammatory drug binding proteins
    Patent number: 5955366
    Abstract: This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: September 21, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: John C. Lee, Jerry L. Adams, Timothy F. Gallagher, David W. Green, John Richard Heys, Peter C. McDonnell, Dean E. McNulty, James E. Strickler, Peter R. Young
  • Cytokine suppressive anit-inflammatory drug binding proteins
    Patent number: 5783664
    Abstract: This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.
    Type: Grant
    Filed: May 31, 1994
    Date of Patent: July 21, 1998
    Assignee: SmithKline Beecham Corporation
    Inventors: John C. Lee, Jerry L. Adams, Timothy F. Gallagher, David W. Green, John Richard Heys, Peter C. McDonnell, Dean E. McNulty, James E. Strickler, Peter R. Young
  • Oligonucleotides comprising a region of a cytokine suppressive anti-inflammatory drug binding protein
    Patent number: 5777097
    Abstract: This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 7, 1998
    Assignee: SmithKline Beecham Corporation
    Inventors: John C. Lee, Jerry L. Adams, Timothy F. Gallagher, David W. Green, John Richard Heys, Peter C. McDonnell, Dean E. McNulty, Peter R. Young, James E. Strickler